Ordinary Re-Weighting | RBC Biotech Opportunities GTR Index | Effective Date 2nd January 2024
RBC Biotech Opportunities GTR Index:
In the ordinary re-weighting, the following composition will be implemented effective open 2nd January 2024:
ABBVIE INC |
ALNYLAM PHARMACEUTICALS INC |
BIOGEN INC |
BIOMARIN PHARMACEUTICAL INC |
GILEAD SCIENCES INC |
INCYTE CORP |
INTRA-CELLULAR THERAPIES INC |
KARUNA THERAPEUTICS INC |
ELI LILLY & CO |
SAREPTA THERAPEUTICS INC |